Nerdwallet Inc vs Pfizer Inc — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $627.09M), while Pfizer Inc trades at $26.55 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 245.9× Nerdwallet Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | PFE | |
|---|---|---|
Market Cap | $627.09M | $154.18B |
Sector | Financials | Health |
52-Week High | $15.93 | $28.56 |
52-Week Low | $7.58 | $23.60 |
Enterprise Value | $541.39M | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.91, up 12.1% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Valuation metrics appear attractive with a P/E of 10.9 and P/S of 0.82.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projected 27.9% upside potential. Key risks include execution challenges in shifting from SEO-dependent referrals and competitive pressure in financial guidance markets. Strong cash flow generation and improving profitability support the bullish case, though investors should monitor quarterly earnings consistency.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Trailing returns across standard periods
Latest headlines on both assets
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →